181 related articles for article (PubMed ID: 20008921)
1. Predictors of damage and survival in patients with Wegener's granulomatosis: analysis of 50 patients.
Kamali S; Erer B; Artim-Esen B; Gul A; Ocal L; Konice M; Aral O; Inanc M
J Rheumatol; 2010 Feb; 37(2):374-8. PubMed ID: 20008921
[TBL] [Abstract][Full Text] [Related]
2. Outcome analysis of patients with vasculitis associated with antineutrophil cytoplasmic antibodies.
Brijker F; Magee CC; Tervaert JW; O'Neill S; Walshe JJ
Clin Nephrol; 1999 Dec; 52(6):344-51. PubMed ID: 10604641
[TBL] [Abstract][Full Text] [Related]
3. Damage caused by Wegener's granulomatosis and its treatment: prospective data from the Wegener's Granulomatosis Etanercept Trial (WGET).
Seo P; Min YI; Holbrook JT; Hoffman GS; Merkel PA; Spiera R; Davis JC; Ytterberg SR; St Clair EW; McCune WJ; Specks U; Allen NB; Luqmani RA; Stone JH;
Arthritis Rheum; 2005 Jul; 52(7):2168-78. PubMed ID: 15986348
[TBL] [Abstract][Full Text] [Related]
4. Baseline features and initial treatment as predictors of remission and relapse in Wegener's granulomatosis.
Koldingsnes W; Nossent JC
J Rheumatol; 2003 Jan; 30(1):80-8. PubMed ID: 12508394
[TBL] [Abstract][Full Text] [Related]
5. Primary systemic vasculitis: clinical features and mortality.
Lane SE; Watts RA; Shepstone L; Scott DG
QJM; 2005 Feb; 98(2):97-111. PubMed ID: 15655098
[TBL] [Abstract][Full Text] [Related]
6. Analysis of early death based on the prediction model in Wegener's granulomatosis with pulmonary and renal involvement.
Zycinska K; Wardyn KA; Tyszko P; Otto M
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):829-37. PubMed ID: 18204197
[TBL] [Abstract][Full Text] [Related]
7. [Wegener's granulomatosis and microscopic polyangiitis].
Pagnoux C
Rev Prat; 2008 Mar; 58(5):522-32. PubMed ID: 18524109
[TBL] [Abstract][Full Text] [Related]
8. Improved outcome in Wegener's granulomatosis and microscopic polyangiitis? A retrospective analysis of 95 cases in two cohorts.
Eriksson P; Jacobsson L; Lindell A; Nilsson JA; Skogh T
J Intern Med; 2009 Apr; 265(4):496-506. PubMed ID: 19141094
[TBL] [Abstract][Full Text] [Related]
9. Clinical features and outcome of pediatric Wegener's granulomatosis.
Akikusa JD; Schneider R; Harvey EA; Hebert D; Thorner PS; Laxer RM; Silverman ED
Arthritis Rheum; 2007 Jun; 57(5):837-44. PubMed ID: 17530684
[TBL] [Abstract][Full Text] [Related]
10. ANCA-associated vasculitis with renal involvement: an outcome analysis.
Weidner S; Geuss S; Hafezi-Rachti S; Wonka A; Rupprecht HD
Nephrol Dial Transplant; 2004 Jun; 19(6):1403-11. PubMed ID: 15069175
[TBL] [Abstract][Full Text] [Related]
11. The role ANCA and anti-GBM antibodies in pulmonary-renal syndrome due to Wegener's granulomatosis.
Zycinska K; Wardyn KA; Zielonka TM; Otto M
J Physiol Pharmacol; 2007 Nov; 58 Suppl 5(Pt 2):839-46. PubMed ID: 18204198
[TBL] [Abstract][Full Text] [Related]
12. ANCA-associated renal vasculitis at the end of the twentieth century--a disease of older patients.
Harper L; Savage CO
Rheumatology (Oxford); 2005 Apr; 44(4):495-501. PubMed ID: 15613403
[TBL] [Abstract][Full Text] [Related]
13. Prospective long-term follow-up of patients with localised Wegener's granulomatosis: does it occur as persistent disease stage?
Holle JU; Gross WL; Holl-Ulrich K; Ambrosch P; Noelle B; Both M; Csernok E; Moosig F; Schinke S; Reinhold-Keller E
Ann Rheum Dis; 2010 Nov; 69(11):1934-9. PubMed ID: 20511614
[TBL] [Abstract][Full Text] [Related]
14. The extent and pattern of organ damage in small vessel vasculitis measured by the Vasculitis Damage Index (VDI).
Mohammad AJ; Bakoush O; Sturfelt G; Segelmark M
Scand J Rheumatol; 2009; 38(4):268-75. PubMed ID: 19296401
[TBL] [Abstract][Full Text] [Related]
15. [Treatment of patients with Wegener's granulomatosis or ANCA-associated vasculitis].
Tervaert JW; Stegeman CA
Ned Tijdschr Geneeskd; 2003 Nov; 147(46):2265-7. PubMed ID: 14655291
[TBL] [Abstract][Full Text] [Related]
16. Etanercept combined with conventional treatment in Wegener's granulomatosis: a six-month open-label trial to evaluate safety.
Stone JH; Uhlfelder ML; Hellmann DB; Crook S; Bedocs NM; Hoffman GS
Arthritis Rheum; 2001 May; 44(5):1149-54. PubMed ID: 11352248
[TBL] [Abstract][Full Text] [Related]
17. Antineutrophil cytoplasmic antibodies reacting with the pro form of proteinase 3 and disease activity in patients with Wegener's granulomatosis and microscopic polyangiitis.
Russell KA; Fass DN; Specks U
Arthritis Rheum; 2001 Feb; 44(2):463-8. PubMed ID: 11229478
[TBL] [Abstract][Full Text] [Related]
18. Intravenous immunoglobulins for relapses of systemic vasculitides associated with antineutrophil cytoplasmic autoantibodies: results of a multicenter, prospective, open-label study of twenty-two patients.
Martinez V; Cohen P; Pagnoux C; Vinzio S; Mahr A; Mouthon L; Sailler L; Delaunay C; Sadoun A; Guillevin L;
Arthritis Rheum; 2008 Jan; 58(1):308-17. PubMed ID: 18163506
[TBL] [Abstract][Full Text] [Related]
19. Survival of patients with Wegener's granulomatosis diagnosed in Finland in 1981-2000.
Takala JH; Kautiainen H; Leirisalo-Repo M
Scand J Rheumatol; 2010; 39(1):71-6. PubMed ID: 20132074
[TBL] [Abstract][Full Text] [Related]
20. Urine IgM excretion predicts outcome in ANCA-associated renal vasculitis.
Bakoush O; Segelmark M; Torffvit O; Ohlsson S; Tencer J
Nephrol Dial Transplant; 2006 May; 21(5):1263-9. PubMed ID: 16449276
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
